Literature DB >> 7712661

Pharmacokinetic considerations in gastrointestinal motor disorders.

G S Hebbard1, W M Sun, F Bochner, M Horowitz.   

Abstract

Although it has been recognised that alterations in gastrointestinal motility, whether induced by physiological or pathological processes, have significant effects on the pharmacokinetics of orally administered drugs, this subject has received inappropriately little attention. Studies relating to this topic have focused on healthy volunteers and animals and have largely been confined to the effects of single drug doses. There is limited information about the effects of disease on pharmacokinetics under steady-state conditions. Changes in gastrointestinal motility may affect the pharmacokinetics of orally administered drugs by altering the rate of delivery, bioavailability or mucosal absorption of the drug. In general the rate of absorption and time taken to achieve maximal plasma concentrations for well absorbed drugs may be modified by changes in gastrointestinal motility, but overall bioavailability is not usually affected. In these cases the therapeutic and clinical effects of the alteration in pharmacokinetics will, therefore, depend on which parameters are important for the action of the drug. For poorly absorbed drugs both the rate of absorption and bioavailability are likely to be altered by changes in gastrointestinal motility. However, the complex effects of food and disease, as well as the properties and formulation of any drug (solubility, ease of dispersion, delayed release formulation) often make the prediction of the magnitude, or even the direction, of any effect difficult to predict. Drugs with direct effects on gastrointestinal motility may influence their own patterns of absorption. In patients with gastrointestinal motility disorders, drugs administered in a controlled release formulation, or those with poor bioavailability, are most likely to have a poorly predictable therapeutic effect. Care should be taken to ensure that the formulation of the drug, its timing of administration in relation to meals and the use of coadministered drugs optimise, or at least ensure consistent absorption.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7712661     DOI: 10.2165/00003088-199528010-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  242 in total

1.  Gastrointestinal adaptation to diets of differing fat composition in human volunteers.

Authors:  K M Cunningham; J Daly; M Horowitz; N W Read
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

2.  Gastric emptying and intragastric distribution of oil in the presence of a liquid or a solid meal.

Authors:  M Edelbroek; M Horowitz; A Maddox; J Bellen
Journal:  J Nucl Med       Date:  1992-07       Impact factor: 10.057

3.  Gastric emptying rates of drug preparations. II. Effects of size and density of enteric-coated drug preparations and food on gastric emptying rates in humans.

Authors:  N Kaniwa; N Aoyagi; H Ogata; A Ejima; H Motoyama; H Yasumi
Journal:  J Pharmacobiodyn       Date:  1988-08

4.  Relations among intragastric pressure, postcibal perception, and gastric emptying.

Authors:  G Moragas; F Azpiroz; J Pavia; J R Malagelada
Journal:  Am J Physiol       Date:  1993-06

5.  Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

6.  Effects of parenteral diclofenac sodium on upper gastrointestinal motility after food in man.

Authors:  G Bassotti; G Bucaneve; C Betti; L Patoia; E Baratta; V Maresca; M A Pelli; A Morelli; A Del Favero
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans.

Authors:  S D Ladas; A Frydas; A Papadopoulos; S A Raptis
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

8.  Reversible lactose malabsorption and intolerance in Graves' disease.

Authors:  A Szilagyi; S Lerman; R G Barr; J Stern; A Colacone; S McMullan
Journal:  Clin Invest Med       Date:  1991-06       Impact factor: 0.825

9.  Absorption of flurbiprofen in the fed and fasted states.

Authors:  J B Dressman; R R Berardi; G H Elta; T M Gray; P A Montgomery; H S Lau; K L Pelekoudas; G J Szpunar; J G Wagner
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

Review 10.  Loperamide. Survey of studies on mechanism of its antidiarrheal activity.

Authors:  F Awouters; A Megens; M Verlinden; J Schuurkes; C Niemegeers; P A Janssen
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

View more
  14 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  Biomagnetic methods: technologies applied to pharmaceutical research.

Authors:  Luciana A Corá; Madileine F Américo; Ricardo B Oliveira; Cristina H R Serra; Oswaldo Baffa; Raul C Evangelista; Giselle F Oliveira; José Ricardo Aruda Miranda
Journal:  Pharm Res       Date:  2010-10-15       Impact factor: 4.200

Review 3.  Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Authors:  S Sabnis
Journal:  Vet Res Commun       Date:  1999-11       Impact factor: 2.459

4.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.

Authors:  A A Nomeir; P Kumari; M J Hilbert; S Gupta; D Loebenberg; A Cacciapuoti; R Hare; G H Miller; C C Lin; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 6.  Medication management on sick days.

Authors:  Tom N Lea-Henry; Jonathan Baird-Gunning; Elizabeth Petzel; Darren M Roberts
Journal:  Aust Prescr       Date:  2017-10-03

7.  Effect of aging on transpyloric flow, gastric emptying, and intragastric distribution in healthy humans--impact on glycemia.

Authors:  Deirdre O'Donovan; Trygve Hausken; Yong Lei; Antonietta Russo; Jennifer Keogh; Michael Horowitz; Karen L Jones
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

8.  The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis.

Authors:  D Sharma; G Morrison; F Joseph; T S Purewal; P J Weston
Journal:  Diabetologia       Date:  2011-08-14       Impact factor: 10.122

9.  Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function.

Authors:  Yukiko Metsugi; Yoshihiro Miyaji; Ken-ichi Ogawara; Kazutaka Higaki; Toshikiro Kimura
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

Review 10.  Diabetic gastroparesis: diagnosis and management.

Authors:  Jing Ma; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.